Debt-to-equity of Lyell Immunopharma, Inc. from 31 Mar 2022 to 30 Sep 2025

Taxonomy & unit: ratio: %
Description: Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary: Lyell Immunopharma, Inc. quarterly Debt-to-equity in % history and change rate from 31 Mar 2022 to 30 Sep 2025.
Lyell Immunopharma, Inc. Debt-to-equity for the quarter ending 30 Sep 2025 was 27%, a 77% increase year-over-year.

Debt-to-equity, Quarterly (%)

Debt-to-equity, YoY Quarterly Change (%)

Lyell Immunopharma, Inc. Quarterly Debt-to-equity (%)

Period	Value	YoY Chg	Change %	Date
Q3 2025	27%	+12%	+77%	30 Sep 2025
Q2 2025	24%	+9.6%	+65%	30 Jun 2025
Q1 2025	21%	+6.6%	+46%	31 Mar 2025
Q4 2024	18%	+4.5%	+34%	31 Dec 2024
Q3 2024	15%	+2.4%	+18%	30 Sep 2024
Q2 2024	15%	+0.33%	+2.3%	30 Jun 2024
Q1 2024	14%	-1.3%	-8.4%	31 Mar 2024
Q4 2023	13%	-4.3%	-24%	31 Dec 2023
Q3 2023	13%	-7%	-35%	30 Sep 2023
Q2 2023	14%	-6.2%	-30%	30 Jun 2023
Q1 2023	15%	-5.7%	-27%	31 Mar 2023
Q4 2022	18%			31 Dec 2022
Q3 2022	20%			30 Sep 2022
Q2 2022	21%			30 Jun 2022
Q1 2022	21%			31 Mar 2022

* An asterisk sign (*) next to the value indicates that the value is likely invalid.